Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $572000.0.

  • Mimedx's Depreciation & Amortization (CF) fell 137.93% to $572000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 2657.13%. This contributed to the annual value of $2.3 million for FY2024, which is 1448.41% down from last year.
  • According to the latest figures from Q3 2025, Mimedx's Depreciation & Amortization (CF) is $572000.0, which was down 137.93% from $558000.0 recorded in Q2 2025.
  • Mimedx's 5-year Depreciation & Amortization (CF) high stood at $1.3 million for Q2 2021, and its period low was $558000.0 during Q1 2024.
  • For the 5-year period, Mimedx's Depreciation & Amortization (CF) averaged around $764611.1, with its median value being $700500.0 (2023).
  • In the last 5 years, Mimedx's Depreciation & Amortization (CF) plummeted by 4106.0% in 2021 and then changed by 0.0% in 2025.
  • Mimedx's Depreciation & Amortization (CF) (Quarter) stood at $973000.0 in 2021, then decreased by 18.19% to $796000.0 in 2022, then decreased by 23.24% to $611000.0 in 2023, then fell by 7.69% to $564000.0 in 2024, then increased by 1.42% to $572000.0 in 2025.
  • Its last three reported values are $572000.0 in Q3 2025, $558000.0 for Q2 2025, and $564000.0 during Q4 2024.